Leah Lawrence

Mid-November 2025 Left untreated, chronic myelogenous leukemia (CML) has a median survival of two to three years.

There was no significant improvement in the hearing thresholds after six months of continuous positive airway pressure (CPAP) therapy among patients with moderate to severe obstructive sleep apnea (OSA), a new study found. However, adherence to CPAP treatment was associated with maintenance of the integrity of the cochlea.

Daniel’s electrocardiogram (ECG) score and derived neutrophil-to-lymphocyte ratio (dNLR) were both good biomarkers for assessing pulmonary thromboembolism (PTE) severity, according to a single-center study by Bojana Uzelac, of the University Clinical Center of Serbia, and colleagues.

The noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) is noninferior to the covalent BTK inhibitor ibrutinib (Imbruvica) in patients with CLL or SLL. These findings are based on results from the first head-to-head phase 3 trial comparing any two BTK inhibitors in a treatment-naïve setting.

Minimal residual disease (MRD) status after induction chemotherapy may be a robust individual-level predictor of overall survival (OS) in patients

January 2026 Data from the IFM2017-03 trial demonstrate that a dexamethasone-sparing regimen with daratumumab and lenalidomide is an acceptable

In recent years, the FDA approved bispecific antibodies for use in patients with multiple myeloma, lymphoma, and other conditions. At least some of these therapies have package labels that require inpatient administration; however, as the number of approvals increases, so does interest in outpatient use.

ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer. 1 The guideline, last updated in 2023 to include first-line therapy recommendations for patients with biomarkers such as PD-L1 and HER2, now reflects new targeted therapy options in the first-line setting, providing the most up-to-date treatment information for clinicians.

The addition of relacorilant (Lifyorli) to nab-paclitaxel resulted in improved overall survival compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, according to results from the final analysis of the phase 3 ROSELLA trial presented at the 2026 SGO Annual Meeting on Women’s Cancer.

Letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II–IV low-grade serous ovarian carcinoma, according to results from the NRG-GY019 trial that were presented at the 2026 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.